Opinion

Video

Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights

Author(s):

Robert Z. Orlowski, MD, PhD,Jonathan L. Kaufman, MD

The experts in relapsed/refractory multiple myeloma care outline their treatment sequencing strategies for patients who have already received T-cell engaging therapies.

Video content above is prompted by the following:

  • What is your treatment sequencing approach for those who already received T-cell engaging therapies?
  • What are some treatment options for those who have already received T-cell directed therapies in the R/R MM setting?
Related Videos
2 KOLs are featured in this series.
Douglas W. Sborov, MD, MS
2 KOLs are featured in this series.
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

Acute Myeloid Leukemia
November 15th 2024

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

Guillermo Garcia-Manero, MD, professor, chief, section of Myelodysplastic Syndromes, deputy chair, Translational Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
August 19th 2024

Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond

RP1 Plus Nivolumab in Advanced Melanoma | Image Credit: © ReisMedia - stock.adobe.com
November 11th 2024

RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy

FDA, EMA Receive Applications for Subcutaneous Daratumumab in High-Risk Smoldering Myeloma
November 8th 2024

FDA, EMA Receive Applications for Subcutaneous Daratumumab in High-Risk Smoldering Myeloma